For most of my life, I carried a background assumption I never examined very closely: if something had been approved, it had already been evaluated. If it was sitting on a shelf, or built into a treatment recommendation, someone with more expertise than me had already asked the hard questions on my behalf. That assumption felt reasonable. It also turned out to be more fragile than I understood.
This is really the second piece of a small cluster on institutional trust — it follows directly from learning to notice the frame a story is presented in. Once you’ve started questioning presentation, the next natural question is what to do with the things presented as officially settled.
Approval Means Accepted, Not Necessarily Safe
The gap between what regulatory approval actually involves and what most people imagine it involves is significant, and it matters in practical ways. Approval processes vary by country, by product category, by the resources of the agency conducting the review, and by the data that was actually submitted for evaluation. What gets approved is what was tested — under the conditions that were tested, for the duration that was tested, often by parties who had a direct financial interest in the outcome. That isn’t automatically wrong. It also isn’t the same thing as independent verification across the full range of conditions a product will eventually be used under.
There’s a documented, formally studied phenomenon economists call regulatory capture — the process by which agencies responsible for overseeing an industry gradually become more aligned with the interests of that industry than with the interests of the public they were established to protect. This isn’t a fringe theory. It traces back to a landmark 1971 paper by the Nobel Prize-winning economist George Stigler, and it’s been studied, debated, and refined by academic economists across the decades since. It happens through a handful of overlapping, well-documented mechanisms: personnel moving between regulatory agencies and the industries they regulate, research funding shaping which questions get asked and which findings get elevated, and the sheer cost and complexity of the approval process itself tending to favor the large, well-resourced players who have both the most to gain from a favorable ruling and the most capacity to influence it.
None of this requires individual corruption. Most people working inside these systems are doing their jobs with real professionalism and real good faith. The dynamic is structural, not personal — when the financial and institutional incentives running through a system point in a particular direction, the system tends to produce outcomes consistent with those incentives, regardless of the character of any individual inside it.
Where the Incentive Goes, the Outcome Often Follows
I didn’t start out thinking in terms of incentives. For a long time it felt like an uncharitable lens — the kind of thinking that assumes the worst about people before they’ve done anything to earn that suspicion. I preferred to take things at face value and assume good faith all around. What actually shifted my thinking wasn’t a change in how I felt about human nature. It was noticing, often enough that I couldn’t keep ignoring it, that the recommendations I kept receiving tended to point in directions that also happened to benefit whoever was making them. That overlap, on its own, proves nothing. But when the pattern holds consistently, the question of incentive stops being uncharitable and starts being simply accurate.
The relationship between financial interest and the shape of information isn’t a secret — it’s documented across industries, research institutions, and the professional bodies that set standards in medicine and beyond. Clinical guidelines are sometimes developed by panels where a meaningful share of members hold financial relationships with the companies whose treatments are under evaluation. Research findings favorable to profitable products are, in aggregate, published at measurably higher rates than findings that complicate them. None of this proves any single guideline is wrong. It means the landscape of guidance is shaped, in consistent and documentable ways, by financial logic running underneath it — understanding incentives rather than hunting for villains is a reason to apply evaluation rather than assume neutrality, not a reason to assume the worst.
Both Can Be True at Once
This is the part worth sitting with directly: something can genuinely help people and also generate real revenue for whoever provides it. Those two things aren’t in tension, and treating them as though they must be is its own kind of oversimplification. A treatment can be effective and profitable. A guideline can be sound and still have been shaped, in part, by the funding structure that produced it. The existence of a financial interest doesn’t automatically invalidate what’s being offered. What it does is make independent evaluation more necessary — not less, and not unnecessary just because good intentions are also genuinely present.
Closing
I want to be careful about where this actually lands, because it’s easy to overcorrect in the other direction. What I’m describing here isn’t paranoia. Paranoia would mean treating everything approved as presumptively dangerous and all official guidance as presumptively deceptive — and that posture isn’t more honest than blind trust. It’s equally unexamined, just pointed the opposite way. What I’m actually describing is discernment: the willingness to apply genuine evaluation to claims, sources, and approvals, rather than treating any of them — in either direction — as self-validating. Most people inside these systems, across the board, are acting in good faith. The point was never that the systems are secretly malicious. It’s that oversight is not the same thing as protection, and treating approval as the end of your own evaluation leaves you dependent on a system whose alignment with your interests is real, but imperfect and variable. That’s exactly the thread the next piece in this cluster picks up — why legal protection, where it exists at all, is almost always retrospective rather than preventive.
Read the Full Story
This post touches two chapters. The full argument is in You Do You.
Sources & Further Reading
Content on Natural Vitality Advocate is provided for educational and informational purposes and may include research-based discussion, personal experience, and opinion. It is not individualized professional advice. Readers should use their own judgment and seek appropriately qualified guidance when making decisions that require individualized professional care. See the full Disclaimer for additional information.